Search

for
Search:

GlossaryNivolumab

immunotherapy drug that helps immune system attack cancer cells

Nivolumab, also known by the brand name Opdivo, is an immunotherapy drug used to treat various types of cancer. It works by blocking a protein called PD-1 on the surface of T-cells, which helps the immune system recognize and attack cancer cells more effectively.

Related Terms

Learn

0 / 0 results

— no results

Research

5 / 61 results

research Persistently Curly Hair Phenotype With the Use of Nivolumab for Squamous Cell Lung Cancer

19 citations, October 2016 in “Journal of oncology pharmacy practice”

A cancer patient's hair became permanently curly after treatment with nivolumab.

research Nivolumab-Induced Alopecia Areata: A Case Report and Literature Review

10 citations, January 2021 in “Annals of dermatology/Annals of Dermatology”

Nivolumab can cause hair loss as a rare side effect.

research Resolution of Paraneoplastic Alopecia Areata Following Nivolumab in a Patient With Metastatic Melanoma

1 citations, June 2023 in “JAAD case reports”

Nivolumab treatment led to hair regrowth in a man with metastatic melanoma and alopecia areata.

research Perifollicular Pink Halo: A Potential Dermoscopic Marker of Inflammation in Central Centrifugal Cicatricial Alopecia

November 2020 in “Journal of The American Academy of Dermatology”

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

research Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy

November 2022 in “Journal of the Endocrine Society”

Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.

View more "nivolumab" in research →

Community Join

0 / 0 results

— no results